Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs.

Maropitant is a neurokinin-1 inhibitor that acts to prevent and treat vomiting by blocking stimuli to the final common pathway in the emetic centre of the brain. The field efficacy and safety of a single oral dose of maropitant were investigated for the prevention of vomiting in dogs with a history of motion sickness resulting from transportation by car in two blinded, placebo-controlled studies. In an exploratory study designed as a two-way crossover trial with 17 dogs, 10 of the dogs given the placebo vomited during a car journey but only three of the dogs vomited under maropitant treatment. In a larger multicentred parallel design study, 69 of 105 dogs treated with the placebo vomited during the journey compared with 15 of 106 dogs treated with maropitant (P < 0.0001).

The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe.

OBJECTIVES: The efficacy of maropitant (Cerenia; Pfizer Inc.) as an anti-emetic for use in dogs with ongoing emesis was evaluated in a two-phase multi-centric study conducted at veterinary clinics in France, Italy, Slovakia and the UK. METHODS: In phase I, dogs with ongoing emesis were randomised in a 1:1 ratio to either maropitant (32 dogs) or metoclopramide (34 dogs). In phase II, dogs were randomised in a 2:1 ratio to maropitant (77 dogs) or metoclopramide (40 dogs). Maropitant was administered subcutaneously at 1 mg/kg/day for up to five days. Metoclopramide was administered as recommended on the product labels as licensed at 0.5 to 1 mg/kg/day subcutaneously or orally with the daily dose divided over two to three administrations per day for up to three to five days. RESULTS: In phase I, 97 per cent of dogs treated with maropitant and 71 per cent of dogs treated with metoclopramide did not vomit after treatment (P<0.01). The mean number of emetic events after maropitant treatment was significantly reduced compared with that after metoclopramide treatment (P=0.01). In phase II, the occurrence of emesis was lower for maropitant during the first 24 hours (P<0.0001) and for each day thereafter. CLINICAL SIGNIFICANCE: A single daily dose of maropitant was more effective than metoclopramide administered two or three times daily in the treatment of emesis caused by various aetiologies in dogs.

Repeatability and reproducibility of germicide tests: a literature review.

The results of a quantitative antimicrobial assay can be summarized by the log reduction value. For an assay to be proposed as a standard method, it is usually necessary to conduct a collaborative study to demonstrate that the repeatability and reproducibility standard deviations (SDs) of the log reduction values are sufficiently small. It is not clear, however, precisely how small those SDs should be. This paper describes the results of a literature review conducted to determine the range of repeatability and reproducibility SDs for standard quantitative antimicrobial assays. The underlying premise is that, for an assay to have been accepted as a standard method, its repeatability and reproducibility SDs must have been sufficiently small. This premise implies that the repeatability and reproducibility SDs of standard assays establish de facto guidelines for acceptability. The survey comprised papers where the SDs could be extracted directly or where they could be calculated from accessible data. Papers describing suspension tests as well as hard surface tests were included. For the standard antimicrobial assays reviewed, repeatability SDs ranged from 0.25 to 1.21 and the reproducibility SDs ranged from 0.31 to 1.54.